DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rebif (Interferon Beta-1a) - Summary

 
 



REBIF SUMMARY

Rebif® (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons.

Rebif® (interferon-beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. Efficacy of Rebif® in chronic progressive multiple sclerosis has not been established.


See all Rebif indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Rebif (Interferon Beta-1A)

PLEGRIDYTM (peginterferon beta-1a) approved in the EU for the treatment of multiple sclerosis
Source: Multiple Sclerosis News From Medical News Today [2014.07.28]
Biogen Idec has announced that the European Commission (EC) has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple...

Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry
Source: MedPageToday.com - medical news plus CME for physicians [2014.09.12]
BOSTON (MedPage Today) -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head again.

more news >>

Published Studies Related to Rebif (Interferon Beta-1A)

Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial. [2012]
USA) and CinnoVex (CinnaGen, Iran)... CONCLUSION: CinnoVex can be used as a safe and effective alternative to Avonex in

Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. [2012]
combined with low-dose azathioprine and prednisone in multiple sclerosis... CONCLUSION: The tested combined therapeutic regimen does not improve long-term

Interferon beta for secondary progressive multiple sclerosis. [2012]
CONCLUSIONS: Well designed RCTs, evaluating a high number of patients

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. [2012]
This study clinically evaluated a novel PEGylated form of interferon beta-1a (PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple sclerosis, in healthy volunteers. Two randomized, blinded phase I studies were conducted: a single-dose study (n = 60) comparing subcutaneous or intramuscular PEG-IFN beta-1a (63, 125, or 188 µg) with intramuscular unmodified IFN beta-1a 30 µg and a multiple-dose study (n = 69) comparing subcutaneous PEG-IFN beta-1a dosed once every 2 or 4 weeks with placebo...

Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. [2011.12.15]
Recent studies have demonstrated the immunomodulatory properties of vitamin D, and vitamin D deficiency may be a risk factor for the development of MS. The risk of developing MS has, in fact, been associated with rising latitudes, past exposure to sun and serum vitamin D status...

more studies >>

Clinical Trials Related to Rebif (Interferon Beta-1A)

Rebif New Formulation (RNF) Quality of Life Study [Active, not recruiting]
To evaluate the impact on Quality of Life, tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif.

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis [Completed]
The purpose of this study is to find out if weekly Avonex works as well as three times a week Rebif in subjects with relapsing multiple sclerosis.

Transition to Rebif New Formulation [Active, not recruiting]
To assess patient satisfaction with respect to the incidence of flu-like symptoms in patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected interferon beta-1a, 44mcg three-times-weekly) to the new formulation of Rebif while receiving ibuprofen either prophylactically or only when necessary (PRN) after the occurance of flu-like symptoms.

Avonex (Interferon-Beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-Remitting MS [Active, not recruiting]
The primary objective of this study is to determine whether combination treatment (adding methylprednisolone to Avonex) reduces progression of disability over 4 years compared to Avonex alone. The study will also investigate whether combination therapy has any impact on the incidence of relapse and brain atrophy as measured by MRI.

Phase II Cladribine Add-on to Inteferon-Beta (IFN-b) Therapy in MS Subjects With Active Disease [Recruiting]
The goal of this study is to evaluate the safety, tolerability and effectiveness of oral cladribine when taken in combination with Interferon-beta therapy for the treatment of MS.

This study will randomize 200 subjects from approximately 50 sites located world-wide, who have experienced at least one relapse while taking Interferon-beta therapy within 48 weeks prior to Screening, irrespective of disability progression. Secondary progressive multiple sclerosis (SPMS) patients, who are still experiencing relapses, and patients who have received disease modifying drugs (DMDs), other than Interferon-beta therapy, during their MS treatment history, but are currently on Interferon-beta therapy and have experienced active MS symptoms (at least 1 relapse) during the 48 weeks prior to Screening, may also be enrolled.

Subjects will be randomised in a 2: 1 fashion to receive up to 4 cycles of oral cladribine or matching placebo in combination with Interferon-beta therapy. Total subject participation is 104 weeks.

more trials >>

Reports of Suspected Rebif (Interferon Beta-1A) Side Effects

Injection Site Erythema (716)Multiple Sclerosis Relapse (680)Injection Site Pain (519)Influenza Like Illness (489)Fall (424)Fatigue (364)Headache (363)Injection Site Haematoma (335)Pain (268)Depression (265)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Rebif has an overall score of 6. The effectiveness score is 8 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
 

Rebif review by 29 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Moderate Side Effects
  
Treatment Info
Condition / reason:   Multiple Sclerosis
Dosage & duration:   250 mg taken 3x weekly for the period of 18 months
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   Reduce number of MS relapses
Side effects:   Flu like symptoms- aches, fever
Comments:   subcutaneous injection 3x weekly

See all Rebif reviews / ratings >>

Page last updated: 2014-09-12

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014